Pfizer (Germany) Top Insiders
| PFE Stock | EUR 23.74 0.15 0.63% |
Pfizer employs about 83 K people. The company is managed by 39 executives with a total tenure of roughly 364 years, averaging almost 9.0 years of service per executive, having 2128.21 employees per reported executive. Examination of Pfizer's management performance can provide insight into the company performance.
| Ian Read Chairman Chairman of the Board, CEO |
| John Young President Group President - Global Established Pharma Business |
Pfizer |
Pfizer Management Team Effectiveness
The company has return on total asset (ROA) of 0.1287 % which means that it generated a profit of $0.1287 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3622 %, meaning that it generated $0.3622 on every $100 dollars invested by stockholders. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.Pfizer Workforce Comparison
Pfizer Inc is considered to be number one stock in number of employees category among related companies. The total workforce of Drug Manufacturers - Major industry is at this time estimated at about 83,373. Pfizer totals roughly 83,000 in number of employees claiming about 100% of equities under Drug Manufacturers - Major industry.
The company has Profit Margin (PM) of 0.31 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.39 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.39. Pfizer Inc Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Pfizer Inc Price Series Summation is a cross summation of Pfizer price series and its benchmark/peer.
Pfizer Notable Stakeholders
A Pfizer stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pfizer often face trade-offs trying to please all of them. Pfizer's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pfizer's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ian Read | Chairman of the Board, CEO | Profile | |
| John Young | Group President - Global Established Pharma Business | Profile | |
| Frank DAmelio | CFO, Executive Vice President - Business Operations | Profile | |
| Douglas Lankler | Executive Vice President General Counsel | Profile | |
| Dawn Rogers | Chief Human Resource Officer, Executive Vice President | Profile | |
| Mikael Dolsten | President - Worldwide Research and Development | Profile | |
| Lidia Fonseca | Executive Vice President CTO and Digital Officer | Profile | |
| Alexander Mackenzie | Executive Vice President Chief Development Officer | Profile | |
| Geno Germano | Group President - Global Innovative Pharma Business | Profile | |
| Laurie Olson | Executive Vice President - Strategy, Portfolio and Commercial Operations | Profile | |
| Sally Susman | Executive Vice President - Corporate Affairs | Profile | |
| Anthony Maddaluna | Executive Vice President and Presidentident - Pfizer Global Supply | Profile | |
| Freda LewisHall | Executive Vice President Chief Medical Officer | Profile | |
| Rady Johnson | Executive Vice President Chief Compliance and Risk Officer | Profile | |
| Charles Hill | Executive Vice President - Worldwide Human Resources | Profile | |
| Albert Bourla | Group President - Vaccines, Oncology and Consumer Healthcare Business | Profile | |
| Kirsten LundJurgensen | Executive Vice President and Presidentident - Pfizer Global Supply | Profile | |
| Angela Hwang | Group President - Pfizer Essential Health | Profile | |
| Kathrin Jansen | Senior Vice President - Vaccine Research & Development | Profile | |
| Michael Goettler | Group President - Pfizer Upjohn | Profile | |
| Helen Hobbs | Independent Director | Profile | |
| Shantanu Narayen | Director | Profile | |
| James Smith | Director | Profile | |
| Dennis Ausiello | Independent Director | Profile | |
| Frances Fergusson | Independent Director | Profile | |
| Stephen Sanger | Independent Director | Profile | |
| Wyllie Cornwell | Independent Director | Profile | |
| Suzanne Johnson | Independent Director | Profile | |
| Dan Littman | Director | Profile | |
| James Kilts | Independent Director | Profile | |
| Don Cornwell | Independent Director | Profile | |
| Joseph Echevarria | Director | Profile | |
| Scott Gottlieb | Director | Profile | |
| Ronald Blaylock | Independent Director | Profile | |
| Jennifer Damico | Controller VP | Profile | |
| Christopher CFA | VP Officer | Profile | |
| David Denton | Chief VP | Profile | |
| DVM DVM | Chairman CEO | Profile | |
| Mikael MD | Dev Research | Profile |
About Pfizer Management Performance
The success or failure of an entity such as Pfizer Inc often depends on how effective the management is. Pfizer management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pfizer management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pfizer management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. PFIZER INC operates under Drug Manufacturers - Major classification in Germany and is traded on Frankfurt Stock Exchange. It employs 92400 people.
The data published in Pfizer's official financial statements usually reflect Pfizer's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Pfizer Inc. For example, before you start analyzing numbers published by Pfizer accountants, it's critical to develop an understanding of what Pfizer's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Pfizer's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pfizer's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Pfizer's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pfizer Inc. Please utilize our Beneish M Score to check the likelihood of Pfizer's management manipulating its earnings.
Pfizer Workforce Analysis
Traditionally, organizations such as Pfizer use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pfizer within its industry.Pfizer Manpower Efficiency
Return on Pfizer Manpower
| Revenue Per Employee | 1.2M | |
| Revenue Per Executive | 2.6B | |
| Net Income Per Employee | 378K | |
| Net Income Per Executive | 804.4M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |